Carlo Russo

Chief Tech/Sci/R&D Officer at GENENTA SCIENCE S.P.A.

Net worth: 2 M $ as of 2024-03-30

71 year

Health Technology

Consumer Services

Profile

Carlo Russo is currently the Chief Medical Officer & Head-Development at Genenta Science SpA since 2021.
Prior to this, he was the President & CEO at VaxInnate Corp.
He also served as the Chief Medical Officer & Executive Vice President at Adverum Biotechnologies, Inc. in 2016.
Dr. Russo holds a doctorate degree from the University of Genoa.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
GENENTA SCIENCE SPA 3.28%	2023-04-18	598,417 ( 3.28% )	2 M $	2024-03-30

Carlo Russo active positions

Companies	Position	Start
GENENTA SCIENCE S.P.A.	Chief Tech/Sci/R&D Officer	2020-12-31

All active positions of Carlo Russo

Former positions of Carlo Russo

Companies	Position	End
ADVERUM BIOTECHNOLOGIES, INC.	Chief Tech/Sci/R&D Officer	2016-06-30
VaxInnate Corp. VaxInnate Corp. Pharmaceuticals: MajorHealth Technology VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ.	Chief Executive Officer	-

See the detail of Carlo Russo's experience

Training of Carlo Russo

University of Genoa

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Carlo Russo's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
ADVERUM BIOTECHNOLOGIES, INC.	Health Technology

Private companies	2
VaxInnate Corp. VaxInnate Corp. Pharmaceuticals: MajorHealth Technology VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ.	Health Technology
Genenta Science SpA